Sign In
Buy BMY
$56.60
+1.88 (+3.44%)
At Close: Jun 04, 2026
Bristol-Myers Q1 Earnings Review: A Decidedly Mixed Bag - Rating Downgrade
11:22am, Thursday, 24'th Apr 2025
Bristol-Myers Squibb Company's Q1 2025 earnings show a 6% YoY revenue decline but improved EPS, with upgraded full-year guidance and a strong dividend yield of over 5%. BMY's growth portfolio is neari
Compared to Estimates, Bristol Myers (BMY) Q1 Earnings: A Look at Key Metrics
10:36am, Thursday, 24'th Apr 2025
The headline numbers for Bristol Myers (BMY) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street est
Bristol Myers Squibb (BMY) Surpasses Q1 Earnings and Revenue Estimates
09:10am, Thursday, 24'th Apr 2025
Bristol Myers Squibb (BMY) came out with quarterly earnings of $1.80 per share, beating the Zacks Consensus Estimate of $1.51 per share. This compares to loss of $4.40 per share a year ago.
Bristol Myers Squibb Posts Better-than-Expected Earnings, Raises Full-Year Guidance
07:13am, Thursday, 24'th Apr 2025
Bristol Myers sees revenue decline in its legacy drug portfolio due to competition and Medicare headwinds.
Bristol Myers posts better-than-expected quarterly revenue on strong cancer drug sales
07:03am, Thursday, 24'th Apr 2025
Bristol Myers Squibb reported better-than-expected first-quarter revenue on Thursday and raised its full-year forecast due to growth from its portfolio of drugs that spur a patient's own immune system
Bristol Myers Squibb tops quarterly estimates, hikes outlook as drugmaker braces for tariffs
07:01am, Thursday, 24'th Apr 2025
Bristol Myers Squibb beat first-quarter estimates and hiked its revenue and profit guidance for the year, as the drugmaker cuts costs. The company said its guidance revisions include the estimated imp
Bristol Myers Squibb Reports First Quarter Financial Results for 2025
06:59am, Thursday, 24'th Apr 2025
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Reports First Quarter Financial Results for 2025.
Bristol Myers Stock Falls After Drug Trial Setback. Why 1 Analyst Isn't Worried.
08:12am, Wednesday, 23'rd Apr 2025
Cobenfy failed to show statistically significant improvement as an adjunctive treatment for schizophrenia, the company said in a statement.
Bristol Myers Sheds 6% After Promising Schizophrenia Drug Flops In Phase 3 Test
05:25pm, Tuesday, 22'nd Apr 2025
Shares of Bristol Myers Squibb tumbled late Tuesday after the company's schizophrenia drug, Cobenfy, failed in a Phase 3 study.
Bristol Myers' Cobenfy fails to meet main goal as add-on treatment for schizophrenia
04:22pm, Tuesday, 22'nd Apr 2025
Bristol Myers Squibb said on Tuesday its drug Cobenfy failed to show a statistically significant difference compared to a placebo in a late-stage trial studying it as a add-on treatment for schizophre
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ARISE--BMS Announces Topline Results from Phase 3 ARISE Trial.
Eli Lilly, Vertex, AbbVie and More Pharma Stocks to Own as Tariffs Loom
11:13am, Tuesday, 22'nd Apr 2025
Trump's tariff policy is the latest uncertainty to plague the pharmaceutical sector.
Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term
10:41am, Tuesday, 22'nd Apr 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Will These 5 Large Drug Maker Stocks Surpass Q1 Earnings Forecast?
10:10am, Tuesday, 22'nd Apr 2025
Let's look at five big pharma companies, GILD, BMY, MRK, ABBV and SNY slated to release their first-quarter 2025 results this week.
Bristol-Myers Squibb: Extraordinary Dividend And FCF Yields Ready For Recession
06:21am, Tuesday, 22'nd Apr 2025
Bristol-Myers Squibb is trading near all-time high dividend and free cash flow yields. BMY stock has a history of outperformance during recessions and bear markets on Wall Street. Relative total retur
